Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2015 Jan 8:9:419-23.
doi: 10.2147/DDDT.S77881. eCollection 2015.

Letter to the editor: naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date

Anna M Buehler  1
Affiliations
Comment

Letter to the editor: naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date

Anna M Buehler. Drug Des Devel Ther. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Meta-analysis of the mean difference of the percentage change in body weight. Abbreviations: SD, standard deviation; IV, inverse variance; CI, confidence interval; df, degrees of freedom; NB, naltrexone sustained-release/bupropion sustained-release.
Figure 2
Figure 2
Meta-analysis of the relative risk of the proportion of patients with at least 5% weight loss. Abbreviations: M-H, Mantel-Haenszel; CI, confidence interval; df, degrees of freedom; NB, naltrexone sustained-release/bupropion sustained-release.
Figure 3
Figure 3
Subgroup analyses – percentage change from baseline in body weight. Abbreviations: CI, confidence interval; mITT-LOCF, modified intention to treat population last observation carried forward; ITT, intention to treat; NB, naltrexone sustained-release/bupropion sustained-release.
Figure 4
Figure 4
Subgroup analyses – relative risk of the loss of at least 5% of one’s body weight. Abbreviations: CI, confidence interval; mITT-LOCF, modified intention to treat population last observation carried forward; ITT, intention to treat; NB, naltrexone sustained-release/bupropion sustained-release.
See this image and copyright information in PMC

Comment on

References

    1. Caixàs A, Albert L, Capel I, Rigla M. Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date. Drug Des Devel Ther. 2014;8:1419–1427. - PMC - PubMed
    1. Gray LJ, Cooper N, Dunkley A, et al. A systematic review and mixed treatment comparison of pharmacological interventions for the treatment of obesity. Obes Rev. 2012;13(6):483–498. - PubMed
    1. James WP, Caterson ID, Coutinho W, et al. SCOUT Investigators Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363(10):905–917. - PubMed
    1. Hollander P, Gupta AK, Plodkowski R, et al. COR-Diabetes Study Group Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36(12):4022–4029. - PMC - PubMed
    1. Apovian CM, Aronne L, Rubino D, et al. COR-II Study Group A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II) Obesity (Silver Spring) 2013;21(5):935–943. - PMC - PubMed

MeSH terms